In partnership with



Your “Safe” Retirement Fund Is Secretly a Bet on AI

If you own an S&P 500 index fund, you probably think your money is spread across 500 companies. It isn’t, not really. A small group of tech giants now makes up a huge share of the index, so a big chunk of every dollar you put in is riding on the same AI trade everyone else is crowded into.

That’s fine while the trade keeps working. But if it cracks, your “diversified” retirement account could fall right along with the most hyped stocks on Wall Street, at the exact moment you can least afford it.

We just put together a free report on 10 stocks that can help balance that out, from gold names that tend to rise when the dollar falls to companies people keep paying in any economy. Get your copy before 2027.



A $247 tool for $7 

MongoDB logo with a cloud icon and stylized server racks and database stack graphics in green tones.

Key Points

  • MongoDB's Atlas platform and growing contracted revenue strengthen its position in enterprise AI applications.
  • GitLab faces growing competition from Microsoft's GitHub and other software providers, putting pressure on its long-term outlook.
  • MongoDB's improving profitability and strong analyst support could give it an advantage, although valuation remains a risk.
  • Special Report: Earn $4,500 a month? Your income may count for more 

 

MongoDB (NASDAQ: MDB) and GitLab (NASDAQ: GTLB) are both positioned for AI-driven strength, but MongoDB may be the better long-term buy. Of the two, GitLab faces a significant competitive threat that could commoditize parts of its business and erode its market share over time.

The primary risk is Microsoft (NASDAQ: MSFT)'s GitHub, which competes directly with GitLab, only at greater scale and backed up by Azure. Each has limits and differentiators, but Microsoft could have the advantage in a head-to-head race. MongoDB, by contrast, has a strong competitive position in enterprise data management and vector search, making it an AI tollbooth insulated from code-layer fluctuations.

And Microsoft isn’t the only long-term threat GitLab faces. While not existential, the cybersecurity industry is steadily encroaching on GitLab’s DevSecOps turf. Datadog (NASDAQ: DDOG) and JFrog (NASDAQ: FROG), which specialize in observability and software artifact management, respectively, are both enabling users with monitoring and security features that overlap with parts of GitLab’s offering. Cloudflare (NYSE: NET), on the other hand, is trying to render traditional security moot with its zero-trust approach. GitLab has a moat, but it’s narrow and getting narrower


Pentagon magnet restrictions take effect January 1, 2027 (Ad)

A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production.

The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing.

The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.

Read the full breakdown of the proposed Army rare earth agreement and the company behind it.



MongoDB: The Models May Change, But the Data Is Forever

MongoDB’s moat is built on its database platform and the costs of switching critical applications to another provider. The catalyst, however, is its Atlas platform, which acts as an enabler for AI applications. It provides data storage, search, and retrieval capabilities enterprises can use to develop, build, and deploy agentic AI at scale. It’s attracting new business and deepening MongoDB's position within existing customer systems.

MongoDB’s second-quarter fiscal year 2027 (FY2027) results revealed sequential and year-over-year business acceleration underpinned by Atlas’s 29% year-over-year growth. Atlas growth is good and remains the story today, but it is the data being generated and entrenchment within existing client ecosystems that matter. Enterprises need their data; the deeper MongoDB is entrenched in their ecosystems, the harder it is for them to switch.

Focused on Fears, the Market Misprices MDB in 2026

Factors the market may be mispricing in Q4 2026 include MongoDB’s growth trajectory, AI disruption, and profitability. While Atlas’ 29% Q2 FY2027 growth failed to impress the analysts, investors should look to the 91% increase in remaining performance obligations (RPO) as a clear sign of momentum. Growth may not accelerate in upcoming quarters, but is likely to be strong, given this metric.

AI disruption, misinterpreting it, supports the thesis that the market is getting MongoDB wrong, as AI cannot exist without data and, more importantly, context. Without context, AI produces gibberish and hallucinations. MongoDB’s utilities help bridge the gap between applications and data by providing a unified interface and real-time context—capabilities enterprises need even when they aren’t building new agents or software.

MongoDB (MDB) stock chart shows shares slipping toward moving-average support amid disruption fears and oversold signals.

Profitability is the factor to watch as the quarters progress. Q2 and H1 fiscal 2027 results showed monetization of investments, scale leverage, and an inflection in GAAP profits, along with adjusted profits and free cash flow the company has been generating. Free cash flow nearly doubled year over year, pointing to a stronger balance sheet and greater capacity for capital returns. MDB doesn’t pay dividends, but it has been repurchasing shares and expanded its buyback authorization to $2 billion in September. GitLab is not GAAP profitable, although it does generate adjusted free cash flow.


A myelin-protecting MS therapy just got the FDA's green light (Ad)

A NASDAQ-listed biotech just received FDA clearance to move its lead multiple sclerosis therapy, Lucid-MS, into Phase 2 clinical trials. Thermo Fisher Scientific's clinical research business has been brought in to help execute the study.

Lucid-MS is designed to protect myelin rather than suppress the immune system. It led to movement recovery, including walking, in a pre-clinical mouse model, and will now be tested in patients with progressive MS for the first time.

Independent commercialization research projects peak annual sales of up to $5 billion. The stock still trades under $5 per share.

Learn why this FDA milestone could matter for the biotech's future



Consensus Firms: MongoDB, Undervalued With Catalysts Ahead

Analyst responses to MongoDB’s fiscal second-quarter report were mixed but generally positive, with several firms raising their price targets while others lowered theirs. MarketBeat data continues to show a Moderate Buy consensus rating, with the average price target suggesting substantial upside from recent trading levels. Overall, analysts remain bullish on MongoDB’s long-term prospects, even as concerns about valuation and the pace of Atlas growth persist.

The question is what may trigger a more bullish stance, and Q3 results are the most visible catalyst. Due Dec. 1, guidance assumes revenue growth will slow to about 20%; the market expects strength. GitLab may also produce a catalyst with its next earnings report, currently expected in December. Trends suggest the amount of AI-generated code is exploding, and GitLab is well-positioned to benefit. Its tools and pricing shifts enable automated workflows and have already helped it deliver an earnings beat despite competitive pressure.

Valuation is a risk for both. Neither stock is cheap, although GitLab's GAAP losses make a direct earnings-multiple comparison difficult. However, the market prices in robust growth trajectories that the latest results have affirmed. In this scenario, hiccups and hurdles will be reflected in the stock prices, but each has triple-digit potential, based on longer-term forecasts.

Read this article online ›pixel

 

Add MarketBeat as a Google Preferred Source

 

Stay Ahead of the Market

The best investment opportunities don't wait. Get our research and stock ideas delivered straight to your smartphone—so you never miss a market-moving opportunity. Our text alerts ensure you see timely stock ideas and professional research reports instantly, whether you're in a meeting, commuting, or away from your desk.

Get Text Alerts from American Market News (free)